NDC 63083-3036-4 HUMAN OTC DRUG

Drug Status:  Active

Proprietary Name: Same Liquescence 3036

Drug Overview

The NDC Code 63083-3036-4 is assigned to “Same Liquescence 3036” (also known as: “Same Liquescence”), a human otc drug labeled by “Professional Complementary Health Formulas”. The product's dosage form is liquid, and is administered via oral form.

Disclaimer

Do not rely on DataLabs to make decisions regarding medical care. Always speak to your health provider about the risks and benefits of FDA-regulated products. We may limit or otherwise restrict your access to the API/WEB in line with our Terms of Service.

Drug Information
NDC Package Code	63083-3036-4
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Product NDC	63083-3036
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
11 Digit NDC Code	63083-3036-04
	It should be noted that many NDCs are displayed on drug packaging in a 10-digit format. Proper billing of an NDC requires an 11-digit number in a 5-4-2 format. Converting NDCs from a 10-digit to 11-digit format requires a strategically placed zero, dependent upon the 10-digit format.
Proprietary Name	Same Liquescence
	Also known as the trade name. It is the name of the product chosen by the labeler.
Non Proprietary Name	Same Liquescence
	Sometimes called the generic name, this is usually the active ingredient(s) of the product.
Product Type Name	HUMAN OTC DRUG
	Indicates the type of product, such as Human Prescription Drug or Human OTC Drug. This data element corresponds to the “Document Type” of the SPL submission for the listing. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Proprietary Name Suffix	3036
	A suffix to the proprietary name, a value here should be appended to the ProprietaryName field to obtain the complete name of the product. This suffix is often used to distinguish characteristics of a product such as extended release (“XR”) or sleep aid (“PM”). Although many companies follow certain naming conventions for suffices, there is no recognized standard.
Labeler Name	Professional Complementary Health Formulas
	Name of Company corresponding to the labeler code segment of the ProductNDC.
Status	Active
	Possible status values: Active Active NDC Code Deprecated Deprecated NDC Code Unfinished (Unapproved) The following status describes submitted unfinished drugs, including the marketing categories of Active Pharmaceutical Ingredient (API), Drug for Further Processing, Bulk for Human Drug Compounding, and Bulk for Animal Drug Compounding. FDA does not review and approve unfinished products. Therefore, all products having "unfinished" status are considered unapproved.

Route & Dosage
Dosage Form Name	LIQUID
	The translation of the DosageForm Code submitted by the firm. The complete list of codes and translations can be found www.fda.gov/edrls under Structured Product Labeling Resources.
Route Name	ORAL
	The translation of the Route Code submitted by the firm, indicating route of administration. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Pharmaceutical Classes	ANALOGS/DERIVATIVES [CHEMICAL/INGREDIENT], BLOOD COAGULATION FACTOR [EPC], CALCIUM [CS], CALCULI DISSOLUTION AGENT [EPC], CATIONS, DIVALENT [CS], COPPER ABSORPTION INHIBITOR [EPC], DECREASED COPPER ION ABSORPTION [PE], INCREASED COAGULATION FACTOR ACTIVITY [PE], INCREASED LARGE INTESTINAL MOTILITY [PE], INCREASED LARGE INTESTINAL MOTILITY [PE], INHIBITION LARGE INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], INHIBITION LARGE INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], INHIBITION SMALL INTESTINE FLUID/ELECTROLYTE ABSORPTION [PE], MAGNESIUM ION EXCHANGE ACTIVITY [MOA], NICOTINIC ACID [EPC], NICOTINIC ACIDS [CS], OSMOTIC ACTIVITY [MOA], OSMOTIC ACTIVITY [MOA], OSMOTIC LAXATIVE [EPC], OSMOTIC LAXATIVE [EPC], PHOSPHATE BINDER [EPC], PHOSPHATE CHELATING ACTIVITY [MOA], POTASSIUM COMPOUNDS [CS], POTASSIUM SALT [EPC], STIMULATION LARGE INTESTINE FLUID/ELECTROLYTE SECRETION [PE], VITAMIN B 12 [CS], VITAMIN B 6 [CHEMICAL/INGREDIENT], VITAMIN B12 [EPC], VITAMIN B6 ANALOG [EPC]
	These are the reported pharmaceutical class categories corresponding to the SubstanceNames listed above.

Substance & Strength
Substance Name	ADEMETIONINE (Substance Adverse Reports) - 3 [hp_X]/118mL ADENOSINE TRIPHOSPHATE (Substance Adverse Reports) - 6 [hp_X]/118mL BOS TAURUS LIMBIC SYSTEM (Substance Adverse Reports) - 8 [hp_X]/118mL CALCIUM LACTATE (Substance Adverse Reports) - 9 [hp_X]/118mL CYANOCOBALAMIN (Substance Adverse Reports) - 4 [hp_X]/118mL FERROUS CATION (Substance Adverse Reports) - 12 [hp_X]/118mL FOLIC ACID (Substance Adverse Reports) - 6 [hp_X]/118mL GLUTATHIONE (Substance Adverse Reports) - 12 [hp_X]/118mL HYPERICUM PERFORATUM WHOLE (Substance Adverse Reports) - 6 [hp_X]/118mL MAGNESIUM GLUCONATE (Substance Adverse Reports) - 15 [hp_X]/118mL METHIONINE (Substance Adverse Reports) - 4 [hp_X]/118mL NIACIN (Substance Adverse Reports) - 6 [hp_X]/118mL PASSIFLORA INCARNATA FLOWERING TOP (Substance Adverse Reports) - 1 [hp_X]/118mL PHOSPHATIDYL SERINE (Substance Adverse Reports) - 6 [hp_X]/118mL PHOSPHATIDYLCHOLINE, SOYBEAN (Substance Adverse Reports) - 6 [hp_X]/118mL POTASSIUM GLUCONATE (Substance Adverse Reports) - 15 [hp_X]/118mL PYRIDOXINE (Substance Adverse Reports) - 6 [hp_X]/118mL SEROTONIN (Substance Adverse Reports) - 12 [hp_X]/118mL THIAMINE (Substance Adverse Reports) - 8 [hp_X]/118mL ZINC GLUCONATE (Substance Adverse Reports) - 9 [hp_X]/118mL
	This is the active ingredient list. Each ingredient name is the preferred term of the UNII code submitted.

Drug Package Information
NDC Package Code	63083-3036-4
	The labeler code, product code, and package code segments of the National Drug Code number, separated by hyphens. Asterisks are no longer used or included within the product and package code segments to indicate certain configurations of the NDC.
Package Description	118 ML IN 1 BOTTLE, DROPPER (63083-3036-4)
	A description of the size and type of packaging in sentence form. Multilevel packages will have the descriptions concatenated together. For example: 4 BOTTLES in 1 CARTON/100 TABLETS in 1 BOTTLE.
Sample Package	N
	Defines whether given package serves sample purposes.
Package NDC Exclude Flag	N
	This indicates whether the package has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.
Package Start Marketing Date	19850815
	This is the date that the labeler indicates was the start of its marketing of the drug package.
Package End Marketing Date	N/S (NOT SPECIFIED)
	This is the date the package will no longer be available on the market. If a package is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Packages that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Packages with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.

Product Application & Marketing Information
Product NDC	63083-3036
	The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
Application Number	N/S (NOT SPECIFIED)
	This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
Marketing Category Name	UNAPPROVED HOMEOPATHIC
	Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
Listing Record Certified Through	20271231
	This is the date when the listing record will expire if not updated or certified by the firm.
Product Marketing Start Date	19840815
	This is the date that the labeler indicates was the start of its marketing of the drug product.
Product Marketing End Date	N/S (NOT SPECIFIED)
	This is the date the product will no longer be available on the market. If a product is no longer being manufactured, in most cases, the FDA recommends firms use the expiration date of the last lot produced as the EndMarketingDate, to reflect the potential for drug product to remain available after manufacturing has ceased. Products that are the subject of ongoing manufacturing will not ordinarily have any EndMarketingDate. Products with a value in the EndMarketingDate will be removed from the NDC Directory when the EndMarketingDate is reached.
Product NDC Exclude Flag	N
	This indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA’s requests for correction to deficient or non-compliant submissions.

Tracking Information
Last Update Date	2026-01-09
	The date that a record was last updated or changed.